WuXi Vaccines, a global contract development and manufacturing organization (CDMO), has entered into an agreement with Harbour BioMed under which Harbour BioMed’s manufacturing facility in Suzhou will be transferred to WuXi Vaccines. The 8,500-square-meter facility includes multiple 250L, 500L and 1000L single-use bioreactors as well as sterile drug-product manufacturing lines. This facility, a new node within WuXi Vaccines global network, will be renovated to provide vaccine developmen...